Mitomycin C und hochdosiertes Medroxyprogesteronacetat in der Therapie des metastasierenden Mammakarzinoms

Publisher Website
Google Scholar
Abstract
Combination therapy with mitomycin C 40 mg/m2 and medroxyprogesterone acetate 1.500 mg/day in patients with refractory metastatic breast cancer was tested in a phase II trial of the AIO. The overall response was 50% with 2 complete and 12 partial remissions. This combination therapy was well tolerated; hematologic toxicity was less than expected. More often, pulmonary and renal toxicity appeared. This combination schedule seems to be useful even in patients with pretreated metastatic breast cancer. Hematologic, pulmonary and renal functions have to be observed.